Scancell Share Discussion Threads

[tosh123] 15/5/2018 08:08

Morning Loz... great news mate.

[oldnotwise] 15/5/2018 07:48

Lozan
Glad they came up with that conclusion, great news!
ATB

[drdobson1] 14/5/2018 20:41

Very good news Lozan.
Hope you have a very nice Red “ chambring” think that is right word to celebrate.
Look forward to your continued input into ensuring the level of debate here stays at its recent high.
Decent day on the share price too.

[bermudashorts] 14/5/2018 20:17

Yep good news Lozan.

[gazza] 14/5/2018 20:13

Also, very good that there have been extremely civilised exchanges the last couple of days.

[gazza] 14/5/2018 20:11

Lozan, glad to hear everything OK.

[torquayfan] 14/5/2018 11:24

Timbo. 15645 Thanks . .

[chelsea35] 14/5/2018 06:47

timbo, thanks for coming back so soon, will pass, this occasion, look forward to reading your thoughts after. Enjoy. Take Care.

[timbo003] 14/5/2018 06:00

>>>Chelsea

I'll be coming up from Woking (by train), but will be in London all day as I've got another (VCT) meeting in the morning.

Helpful hint to all: when copying a "censored" ULR from ADVFN to LSE, try converting it to a short URL first, for example, the events page for ShareSoc will not copy in its entirety to LSE, but if you shorten it here: it overcomes the problem:



becomes:

[chelsea35] 14/5/2018 03:50

Lozan, goog luck t you at cardiologist.

[chelsea35] 14/5/2018 03:48

Timbo, would love to go, where are you you going from to.?

atb

[gooosed] 13/5/2018 21:38

It's encouraging that the comparative advantages of SCIB1 seem to endure & if it is found that Nano-vesicle delivery brings something else to the table (LD must have been consulted ?!) so much the better.

[bermudashorts] 13/5/2018 21:07

Thanks for that gooosed. As you know, this is the original intended setting for SCIB1 (ie. as an adjuvant therapy following surgery to prevent return of cancer). Yervoy has already been approved as an adjuvant therapy but the PD1's are coming along and based on data released so far must surely receive FDA approval. So these ongoing results from the Keytruda trial are worth keeping an eye on. With the huge caveat that Scancell's patient nos. are very small it's interesting to see how they compare.

1) Keytruda trial is in patients with stage III melanoma whereas SCIB1 trial is stage III and stage IV

2) 1 year recurrence free survival - Keytruda = 75.4% SCIB1 = 100%

3) Treatment related (grade 3-5) adverse events - Keytruda = 14.7% SCIB1 = 0%

4) Treatment related deaths - Keytruda = 1 SCIB1 = 0

5) Cost of treatment for 1 year - Keytruda = approx. $150k SCIB1 = ?? much less!!

Would love to see SCIB1 put through a large randomised trial as an adjuvant therapy. Putting Scancell to one side though, it's amazing to see how melanoma treatment has advanced during the past 5 years or so.

[gooosed] 13/5/2018 20:19

"CONCLUSIONS
As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594; EudraCT number, 2014-004944-37.)"

[gooosed] 13/5/2018 13:25

Looking forward to your report back Timbo - maybe there will be some info on Nano-vesicle delivery ?

Lozan - best of luck for tomorrow.

[torquayfan] 13/5/2018 00:15

OK Loz. GL.

[timbo003] 12/5/2018 19:17

Scancell will be presenting at the ShareSoc Growth Company Seminar next Wednesday along with two other Aim listed companies with oncology interests (Evgen and Angle):



I've booked my place and will report back in due course. Anyone else planning to go along?

[bermudashorts] 12/5/2018 17:15

From Krafty on lse - this is great news

6 years after original announcement of Moditope and the rush to 64p, the European Patent for Moditope has been formally granted. There is a publishing date of June 13th, so do not know when this will be announced by the company formally but this is a massive step forward and opens the door for any official commercial opportunities that may have been pending to the official granting, So with SC1B1 and 2 moving swiftly forward to trials, and all that is happening with Moditope including the Grand Challenge and over £10m in the bank, these are exciting times. Nice to talk about facts and not conjecture.

[bermudashorts] 12/5/2018 16:56

Yep, hope all goes well with the cardiologist on Monday Lozan.

[torquayfan] 12/5/2018 15:20

Hello Lozan.

Just saying - you have made your point thoroughly enough.
If you do relieve stress with this stuff - carry on !

Hope it goes well. I'd say the object of the game is not avoiding LOSSES but to get better as much as possible. GL.

[the real lozan] 12/5/2018 11:43

Tarquin Eetup -
Thank you for those kind words
BUT
What makes you think = "And the stress stuff on here won't help you either."
That there is any " stress stuff on here" for me or other folks who remain focused on the REALITY ???.
I am quite sure you would 'prefer' myself and others to "Give up" pointing out the 'dangers' of FALSE CLAIMS and trHYPE
I CAN assure everyone - There is NO 'stress' or 'distress' for anyone who is not fooled by trHYPE and CLEARLY FALSE CLAIMS that are PROVEN to lead to LOSSES.
The object of 'the game' is to avoid LOSSES
Don't you agree ???